Researcher Profile

S.M. Tolaney

0000-0002-5940-8671

Publications

580

Citations

Co-Authors

Active Years

Publications

Open Access Journal Article ESMO Open Mar 01, 2026

Genomic landscape, immune microenvironment and survival in male versus female breast cancer

D. Trapani · S.K. Deshmukh · T. Samec · S. Wu +12 more

10.1016/j.esmoop.2026.106059

Open Access Journal Article ESMO Open Mar 01, 2026

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer

A. Grinshpun · D. Dustin · M. Cai · M. Hughes +11 more

10.1016/j.esmoop.2026.106067

Open Access Journal Article ESMO Open Mar 01, 2026

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials

K. Jhaveri · F.C. Bidard · K. Kalinsky · P. Neven +8 more

10.1016/j.esmoop.2026.106091

Open Access Journal Article Annals of Oncology Feb 01, 2026

Overall survival with abemaciclib in early breast cancer

S. Johnston · M. Martin · J. O’Shaughnessy · R. Hegg +23 more

10.1016/j.annonc.2025.10.005 20 citations

Journal Article JNCI Journal of the National Cancer Institute Aug 14, 2025

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer

Paolo Tarantino · Dong-Gun Lee · Julia Foldi · Pamela R Soulos +11 more

10.1093/jnci/djaf220 6 citations

Journal Article Annals of Oncology Sep 01, 2025

LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest

S. Loibl · Z. Jiang · R. Barroso-Sousa · Y.H. Park +15 more

10.1016/j.annonc.2025.09.028 2 citations

Open Access Journal Article Annals of Oncology Mar 01, 2024

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial

L.M. Spring · S.M. Tolaney · G. Fell · V. Bossuyt +19 more

10.1016/j.annonc.2023.11.018 56 citations

Open Access Journal Article Annals of Oncology Jun 01, 2022

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

H.S. Rugo · J. O’Shaughnessy · F. Boyle · M. Toi +18 more

10.1016/j.annonc.2022.03.006 116 citations

Open Access Journal Article Annals of Oncology Sep 01, 2021

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

A. Bardia · S.M. Tolaney · K. Punie · D. Loirat +23 more

10.1016/j.annonc.2021.06.002 254 citations

Open Access Journal Article Annals of Oncology Dec 01, 2020

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

K. Kalinsky · J.R. Diamond · L.T. Vahdat · S.M. Tolaney +12 more

10.1016/j.annonc.2020.09.004 126 citations

Publication Timeline

2026

2025

2024

2022

2021

2020

Frequent Co-Authors

4×

4×

3×

3×

2×

2×

2×

2×

2×

2×